Skip to contentB
BridgeBio Pharma, Inc.
B
BBIOBridgeBio Pharma, Inc. Q2 2026 · 10-Q
Revenue$243.68M$243.68M+120.4% vs Q2 2025 Net Income-$155.89M-$155.89MN/M vs Q2 2025 EPS Diluted-$0.78-$0.78N/M vs Q2 2025 Operating Income-$107,079,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$71,544,000N/M Margins · derivedOperating margin-43.9%+77.5 pt vs Q2 2025
Net margin-64.0%+102.2 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 10, 2026 · 41 d after period end